Loading...
On November 10, 2010, the FDA approved the growth hormone-releasing factor analogue tesamorelin (Egrifta) for the treatment of visceral fat accumulation in HIV-infected patients. The approval was based on two industry-sponsored, phase III clinical trials, in which more than 800 patients were randomized to receive daily subcutaneous injections of tesamorelin (2 mg) or placebo (J Clin Endocrinol Metab 2010; 95:4291). After 26 weeks of treatment, tesamorelin recipients had significant reductions in visceral fat, with no change in subcutaneous fat, and substantial improvements in body image. The most common adverse effects reported were arthralgia, pain in the extremities, myalgia, injection-site reactions, and peripheral edema.